# Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct07527078` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07527078](<https://clinicaltrials.gov/study/NCT07527078>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07527078

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.

## Technical summary

Registry record NCT07527078. Randomized; no masking; primary purpose treatment. Start 2026-04-07 (actual); primary completion 2026-04-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 350 participants (planned count; ClinicalTrials.gov record NCT07527078, source copy `cardio:ctgov-nct07527078-2026-07-01`, retrieved 2026-10-26)
- Started: 2026-04-07 (actual) (ClinicalTrials.gov record NCT07527078, source copy `cardio:ctgov-nct07527078-2026-07-01`, retrieved 2026-10-26)
- Primary completion: 2026-04-07 (actual) (ClinicalTrials.gov record NCT07527078, source copy `cardio:ctgov-nct07527078-2026-07-01`, retrieved 2026-10-26)
- Completion: 2027-04-17 (anticipated) (ClinicalTrials.gov record NCT07527078, source copy `cardio:ctgov-nct07527078-2026-07-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07527078, source copy `cardio:ctgov-nct07527078-2026-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07527078-2026-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes (T2DM)
- Intervention (Drug): GZR33 Injection
- Intervention (Drug): Insulin Degludec Injection (Tresiba®)
- Lead sponsor: Gan & Lee Pharmaceuticals.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Gan & Lee Pharmaceuticals. (`cardio:org-gan-lee-pharmaceuticals`)

## Provenance

Content hash: 823b6cd473cd8f83bddc4ba551bf756d559ab8399c9169ce570bf0cb33e6729e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
